Kolexia
Willekens Christophe Hématologie
Willekens Christophe
Hématologie
Gustave-Roussy
Villejuif, France
138 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie myéloïde Leucémie aigüe myéloïde Syndromes myélodysplasiques Leucémie myélomonocytaire chronique Lymphomes COVID-19 Tumeurs hématologiques Maladie de Hodgkin

Collaborateurs

Voir plus
De Botton Stephane
De Botton Stephane
Gustave-Roussy, Villejuif, France
Saada Veronique
Saada Veronique
Gustave-Roussy, Villejuif, France
Solary Eric
Solary Eric
Gustave-Roussy, Villejuif, France
Micol Jean-Baptiste
Micol Jean-Baptiste
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Abbvie
5 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2022
LVL Medical
1 collaboration(s)
Dernière en 2022
Sandoz
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS): A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Essai Clinique (BMS)   13 mars 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Essai Clinique (Celgene)   08 février 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
65th ASH Annual Meeting Abstracts   02 novembre 2023
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation: A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Essai Clinique (Servier)   02 novembre 2023
Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia
65th ASH Annual Meeting Abstracts   02 novembre 2023
Leucémie myéloïde : symptômes, diagnostic et traitements
Femme actuelle   31 juillet 2023
When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.
EJHaem   19 mai 2023